4basebio PLC (88Q.DE)
EUR 14.6
(0.0%)
EUR 14.6
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 506 Thousand GBP | 88.81% |
| 2022 | 268 Thousand GBP | -20.71% |
| 2021 | 338 Thousand GBP | -26.84% |
| 2020 | 462 Thousand GBP | 128.71% |
| 2019 | 202 Thousand GBP | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 387.15 Thousand EUR | 0.0% |
| 2023 Q4 | 309.09 Thousand EUR | 11.6% |
| 2023 FY | 506 Thousand GBP | 88.81% |
| 2023 Q2 | 276.96 Thousand EUR | 111.29% |
| 2022 Q4 | 131.08 Thousand EUR | -25.74% |
| 2022 FY | 268 Thousand GBP | -20.71% |
| 2022 Q2 | 176.52 Thousand EUR | -6.65% |
| 2021 Q2 | 208.51 Thousand EUR | -38.4% |
| 2021 FY | 338 Thousand GBP | -26.84% |
| 2021 Q4 | 189.09 Thousand EUR | -9.31% |
| 2020 Q2 | 174.91 Thousand EUR | 0.0% |
| 2020 FY | 462 Thousand GBP | 128.71% |
| 2020 Q4 | 338.51 Thousand EUR | 93.52% |
| 2019 FY | 202 Thousand GBP | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| BioNTech SE | 3.81 Billion EUR | 99.987% |
| CureVac N.V. | 53.75 Million EUR | 99.059% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 99.926% |
| Biotest Aktiengesellschaft | 684.6 Million EUR | 99.926% |
| BRAIN Biotech AG | 55.33 Million EUR | 99.086% |
| Formycon AG | 77.69 Million EUR | 99.349% |
| Heidelberg Pharma AG | 9.85 Million EUR | 94.868% |
| Medigene AG | 6.03 Million EUR | 91.614% |